TDY:NYSETeledyne Technologies Incorporated Analysis
Data as of 2026-05-27 - not real-time
$614.35
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Teledyne Technologies (TDY) is currently trading below its 20‑day simple moving average, suggesting a short‑term price deficit that could be closed if buying pressure resumes.
The 14‑day RSI sits in the mid‑40s, indicating modest oversold momentum, while the MACD line remains bearish, reinforcing a cautious near‑term outlook.
Fundamentally, the company posts a price‑to‑earnings multiple well beneath its industry peer average, a robust gross margin, and a healthy operating cash flow, all of which point toward intrinsic value that exceeds the market price.
However, the stock exhibits elevated 30‑day volatility, a near‑neutral beta, and a sizable max drawdown history, which together raise the risk profile despite the absence of dividend yield.
The 14‑day RSI sits in the mid‑40s, indicating modest oversold momentum, while the MACD line remains bearish, reinforcing a cautious near‑term outlook.
Fundamentally, the company posts a price‑to‑earnings multiple well beneath its industry peer average, a robust gross margin, and a healthy operating cash flow, all of which point toward intrinsic value that exceeds the market price.
However, the stock exhibits elevated 30‑day volatility, a near‑neutral beta, and a sizable max drawdown history, which together raise the risk profile despite the absence of dividend yield.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price below 20‑day SMA indicating near‑term upside potential
- RSI in the mid‑40s and bearish MACD suggesting limited immediate momentum
- stable volume and elevated short‑term volatility
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- PE ratio markedly lower than industry average
- strong operating cash flow and solid margins
- upside potential of roughly 20% above current price
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- consistent revenue growth and robust free cash flow generation
- fair valuation relative to peers despite sector‑specific risks
- absence of dividend but strong reinvestment capacity
Key Metrics & Analysis
Financial Health
Revenue Growth7.60%
Profit Margin14.99%
P/E Ratio31.2
ROE9.05%
ROA4.89%
Debt/Equity23.13
P/B Ratio2.7
Op. Cash Flow$1.2B
Free Cash Flow$760.6M
Industry P/E40.3
Technical Analysis
TrendNeutral
RSI44.1
Support$599.57
Resistance$654.05
MA 20$627.32
MA 50$631.31
MA 200$582.22
MACDBearish
VolumeStable
Fear & Greed Index91.95
Valuation
Fair Value$253.36
Target Price$734.54
Upside/Downside19.56%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.00
Volatility24.80%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.